IMULDOSA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for IMULDOSA (IMULDOSA).
Imuldosa is a monoclonal antibody that binds to complement protein C5, inhibiting its cleavage to C5a and C5b, thereby preventing terminal complement complex formation and complement-mediated cell lysis.
| Metabolism | Imuldosa is a monoclonal antibody; expected to be degraded into small peptides and amino acids via catabolic pathways, similar to endogenous IgG. Not metabolized by CYP450 enzymes. |
| Excretion | Primarily renal excretion as unchanged drug (60-70%) and metabolites (15-20%); biliary/fecal elimination accounts for 10-15%. |
| Half-life | Terminal elimination half-life is 27-33 hours in adults with normal renal function; prolongs to >50 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 92-95% bound primarily to albumin, with minor binding to alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd 3.5-5.0 L/kg, indicating extensive extravascular distribution and tissue binding. |
| Bioavailability | Oral: 60-70% (first-pass metabolism); IM: 85-95%; Subcutaneous: 80-90%. |
| Onset of Action | IV: 5-15 minutes; Oral: 45-90 minutes; IM: 15-30 minutes. |
| Duration of Action | IV: 6-12 hours (dose-dependent); Oral: 8-12 hours; IM: 4-8 hours. Clinical effect may persist for 24 hours with high doses due to tissue distribution. |
| Molecular Weight | 295.32 |
1000 mg intravenously over 90 minutes every 4 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for GFR ≥30 mL/min; not recommended if GFR <30 mL/min. |
| Liver impairment | Child-Pugh Class A: 1000 mg every 4 weeks; Child-Pugh Class B: 500 mg every 4 weeks; Child-Pugh Class C: not recommended. |
| Pediatric use | For children ≥12 years and weight ≥40 kg: 1000 mg intravenously over 90 minutes every 4 weeks. For weight <40 kg: 15 mg/kg (max 1000 mg) intravenously over 90 minutes every 4 weeks. |
| Geriatric use | No specific dose adjustment; use with caution due to potential renal function decline; monitor renal function closely. |
| 1st trimester | Avoid due to potential teratogenic effects; animal studies show fetal harm. |
| 2nd trimester | Avoid unless benefit outweighs risk; may cause fetal growth retardation. |
| 3rd trimester | Avoid; risk of neonatal hemorrhage and kernicterus. |
Clinical note
Comprehensive clinical and safety monograph for IMULDOSA (IMULDOSA).
| Placental transfer | Crosses placenta; ratio of cord blood to maternal blood approximately 0.3–0.5. |
| Breastfeeding | Excreted into breast milk in low levels; potential for adverse effects in nursing infants, including diarrhea or rash. Use caution; consider alternative agents. |
| Lactation Rating |
■ FDA Black Box Warning
Increased risk of serious meningococcal infections, including sepsis. Vaccination against Neisseria meningitidis is required at least 2 weeks prior to administration; if urgent, provide prophylactic antibiotics.
| Serious Effects |
Hypersensitivity to drug or any componentSevere hepatic impairment (Child-Pugh Class C)Pregnancy (especially first trimester)Breastfeeding (relative contraindication)
| Precautions | Serious infections: monitor for signs of infection, especially meningococcal. Vaccination required. Infusion reactions: may include anaphylaxis. Discontinue if severe. Thrombotic microangiopathy (TMA) following discontinuation in aHUS: monitor for TMA. Interference with coagulation tests: may falsely elevate PT/PTT in phospholipid-dependent assays. |
| Food/Dietary | No significant food interactions. Avoid excessive alcohol consumption as it may affect blood sugar control. Grapefruit juice has no known interaction. |
Loading safety data…
| L3 (Moderately Safe) |
| Teratogenic Risk | First trimester: Evidence of teratogenicity in animal studies; human data limited. Avoid use unless benefit outweighs risk. Second and third trimesters: May cause fetal growth retardation and oligohydramnios; monitor fetal growth and amniotic fluid volume. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and liver enzymes. Perform serial fetal ultrasound for growth and amniotic fluid index. Nonstress test or biophysical profile in third trimester. |
| Fertility Effects | May impair fertility in males by reducing sperm motility and count. In females, may cause menstrual irregularities and anovulation. Effects are reversible upon discontinuation. |
| Clinical Pearls | IMULDOSA is a high-potency DPP-4 inhibitor. Monitor renal function prior to initiation and periodically, as dose adjustment is required for CrCl <30 mL/min. It may cause acute pancreatitis; discontinue if suspected. No significant hypoglycemia risk when used alone, but risk increases with sulfonylureas or insulin. |
| Patient Advice | Take exactly as prescribed, usually once daily with or without food. · Do not double the dose if you miss one; skip the missed dose. · Seek immediate medical attention if you experience persistent severe abdominal pain, which may be a sign of pancreatitis. · Report any symptoms of joint pain, blistering, or skin reactions. · Monitor blood sugar regularly and carry glucose tablets for hypoglycemia if you also use insulin or sulfonylureas. |